Literature DB >> 22261897

Endothelial dysfunction in type 2 diabetes.

A Natali1, E Ferrannini.   

Abstract

The mechanisms responsible for the accelerated atherosclerosis observed in type 2 diabetes are not fully understood. One of the earliest events in the development of atherosclerosis is endothelial dysfunction, namely, a reduction in nitric oxide (NO) synthesis or its bioavailability within the peri-endothelial environment, where it is responsible for maintenance of vascular tissue integrity. The clinical evaluation of this pathway is hampered by the fact that in vivo NO cannot be directly measured; however, exploiting a novel, complex and elegant experimental setup, McVeigh and co-workers (Diabetologia 1992;35:771-776) were the first to document that NO bioavailability in type 2 diabetic patients is indeed reduced. In this edition of 'Then and now' that paper is reappraised not only for its originality, but also for the broad and extensive evaluation of the vascular functions explored, the complete clinical characterisation of patients enrolled and for the fact that all the major findings were subsequently replicated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22261897     DOI: 10.1007/s00125-011-2445-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  32 in total

1.  Increased activity of endogenous endothelin in patients with type II diabetes mellitus.

Authors:  Carmine Cardillo; Umberto Campia; Melissa B Bryant; Julio A Panza
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

Review 2.  Cell-derived microparticles in the pathogenesis of cardiovascular disease: friend or foe?

Authors:  Maarten E Tushuizen; Michaela Diamant; Augueste Sturk; Rienk Nieuwland
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01       Impact factor: 8.311

3.  Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events.

Authors:  Ronen Rubinshtein; Jeffrey T Kuvin; Morgan Soffler; Ryan J Lennon; Shahar Lavi; Rebecca E Nelson; Geralyn M Pumper; Lilach O Lerman; Amir Lerman
Journal:  Eur Heart J       Date:  2010-02-24       Impact factor: 29.983

4.  Vasodilation with sodium nitroprusside does not improve insulin action in essential hypertension.

Authors:  A Natali; A Quiñones Galvan; N Pecori; G Sanna; E Toschi; E Ferrannini
Journal:  Hypertension       Date:  1998-02       Impact factor: 10.190

5.  Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans.

Authors:  M A Creager; J P Cooke; M E Mendelsohn; S J Gallagher; S M Coleman; J Loscalzo; V J Dzau
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

6.  Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes.

Authors:  Andrea Natali; Elena Toschi; Stephanie Baldeweg; Demetrio Ciociaro; Stefania Favilla; Luigi Saccà; Ele Ferrannini
Journal:  Diabetes       Date:  2006-04       Impact factor: 9.461

7.  Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension.

Authors:  R Butler; A D Morris; J J Belch; A Hill; A D Struthers
Journal:  Hypertension       Date:  2000-03       Impact factor: 10.190

8.  Upregulation of TNF-alpha and Receptors Contribute to Endothelial Dysfunction in Zucker Diabetic Rats.

Authors:  Xue Gao; Andrea Picchi; Cuihua Zhang
Journal:  Am J Biomed Sci       Date:  2010

Review 9.  Impaired microvascular perfusion: a consequence of vascular dysfunction and a potential cause of insulin resistance in muscle.

Authors:  Michael G Clark
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-08       Impact factor: 4.310

Review 10.  Hemodynamic actions of insulin.

Authors:  A D Baron
Journal:  Am J Physiol       Date:  1994-08
View more
  7 in total

Review 1.  Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.

Authors:  Niina Matikainen; Marja-Riitta Taskinen
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

Review 2.  The Central Role of Endothelial Dysfunction in Cardiorenal Syndrome.

Authors:  Jun Zhang; Teodoro Bottiglieri; Peter A McCullough
Journal:  Cardiorenal Med       Date:  2016-12-29       Impact factor: 2.041

3.  Angiotensin-converting enzyme inhibition and food restriction restore delayed preconditioning in diabetic mice.

Authors:  Gerry Van der Mieren; Ines Nevelsteen; Annelies Vanderper; Wouter Oosterlinck; Willem Flameng; Paul Herijgers
Journal:  Cardiovasc Diabetol       Date:  2013-02-23       Impact factor: 9.951

Review 4.  Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?

Authors:  Wellington Santana da Silva Júnior; Amélio Fernando de Godoy-Matos; Luiz Guilherme Kraemer-Aguiar
Journal:  Biomed Res Int       Date:  2015-06-04       Impact factor: 3.411

5.  Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA.

Authors:  Aline Fofonka; Jorge Pinto Ribeiro; Karina Rabello Casali; Beatriz D Schaan
Journal:  Trials       Date:  2014-11-04       Impact factor: 2.279

Review 6.  To the Future: The Role of Exosome-Derived microRNAs as Markers, Mediators, and Therapies for Endothelial Dysfunction in Type 2 Diabetes Mellitus.

Authors:  Maurice B Fluitt; Neal Mohit; Kanwal K Gambhir; Gail Nunlee-Bland
Journal:  J Diabetes Res       Date:  2022-02-21       Impact factor: 4.011

7.  Sirt6 mRNA-incorporated endothelial microparticles (EMPs) attenuates DM patient-derived EMP-induced endothelial dysfunction.

Authors:  Tong Jing; Kuang Ya-Shu; Wang Xue-Jun; Hou Han-Jing; Lai Yan; Yao Yi-An; Chen Fei; Liu Xue-Bo
Journal:  Oncotarget       Date:  2017-12-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.